Merck & Co., Inc. (NYSE:MRK) Stake Raised by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC boosted its holdings in Merck & Co., Inc. (NYSE:MRK) by 3.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 425,477 shares of the company’s stock after acquiring an additional 13,489 shares during the quarter. Merck & Co., Inc. comprises about 0.5% of Mutual of America Capital Management LLC’s investment portfolio, making the stock its 20th biggest holding. Mutual of America Capital Management LLC’s holdings in Merck & Co., Inc. were worth $32,736,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of MRK. Banco Santander S.A. increased its stake in Merck & Co., Inc. by 11.4% in the 1st quarter. Banco Santander S.A. now owns 271,617 shares of the company’s stock worth $20,899,000 after purchasing an additional 27,758 shares in the last quarter. Novare Capital Management LLC increased its stake in Merck & Co., Inc. by 31.1% in the 4th quarter. Novare Capital Management LLC now owns 4,393 shares of the company’s stock worth $400,000 after purchasing an additional 1,043 shares in the last quarter. Aviva PLC increased its stake in Merck & Co., Inc. by 5.5% in the 4th quarter. Aviva PLC now owns 1,633,882 shares of the company’s stock worth $148,602,000 after purchasing an additional 85,045 shares in the last quarter. Shoker Investment Counsel Inc. increased its stake in Merck & Co., Inc. by 1.9% in the 4th quarter. Shoker Investment Counsel Inc. now owns 22,031 shares of the company’s stock worth $2,003,000 after purchasing an additional 417 shares in the last quarter. Finally, Alliance Wealth Management Group increased its stake in Merck & Co., Inc. by 42.9% in the 4th quarter. Alliance Wealth Management Group now owns 10,390 shares of the company’s stock worth $945,000 after purchasing an additional 3,118 shares in the last quarter. Hedge funds and other institutional investors own 75.25% of the company’s stock.

In related news, Director Wendell P. Weeks sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $76.02, for a total value of $380,100.00. Following the completion of the sale, the director now owns 5,100 shares of the company’s stock, valued at approximately $387,702. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.28% of the company’s stock.

Shares of NYSE MRK traded down $0.18 during trading hours on Friday, hitting $76.37. The stock had a trading volume of 6,046,385 shares, compared to its average volume of 10,529,766. The company has a market capitalization of $193.22 billion, a P/E ratio of 19.33, a P/E/G ratio of 2.12 and a beta of 0.50. The firm’s 50-day moving average price is $79.51 and its two-hundred day moving average price is $83.36. Merck & Co., Inc. has a 52 week low of $65.25 and a 52 week high of $92.64. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.87 and a current ratio of 1.11.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $1.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.34 by $0.16. The business had revenue of $12.06 billion during the quarter, compared to analysts’ expectations of $11.46 billion. Merck & Co., Inc. had a return on equity of 52.46% and a net margin of 21.10%. The firm’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.22 EPS. As a group, analysts expect that Merck & Co., Inc. will post 5.31 EPS for the current fiscal year.

A number of equities analysts recently weighed in on the company. Royal Bank of Canada dropped their price target on Merck & Co., Inc. from $92.00 to $89.00 and set a “sector perform” rating on the stock in a research note on Wednesday, April 1st. UBS Group dropped their price target on Merck & Co., Inc. from $96.00 to $92.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Morgan Stanley lowered their target price on Merck & Co., Inc. from $97.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, April 2nd. Guggenheim lowered their target price on Merck & Co., Inc. from $101.00 to $93.00 and set a “buy” rating on the stock in a research note on Wednesday, April 29th. Finally, Mizuho reaffirmed a “buy” rating on shares of Merck & Co., Inc. in a research note on Wednesday, February 5th. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $93.60.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: How do CD ladders protect against rising interest rates?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.